We’ve known for a while that the gut microbiome shapes both cancer risk and treatment response. What’s exciting now is how quickly this field is moving from theory into practice. The idea is simple but powerful: if the “wrong” microbes can blunt immune therapies or fuel inflammation, then shifting the microbiome might tip the balance back in our favor.
Why FMT?
I get it—transferring stool from a complete stranger—albeit a healthy donor—into you is anything but glamorous. Yet fecal microbiota transplant (FMT) has shown remarkable potential. In small melanoma trials, patients who weren’t responding to checkpoint inhibitors began to respond again after receiving FMT from “super responder” donors. The immune system lit back up.
The challenge is inconsistency — donor differences, patient biology, and safety concerns all add variability. And while FMT is FDA-approved for recurrent C. difficile infection, using it in cancer raises valid questions about infection risk in immunocompromised patients. Regulators are cautious and for good reason.
Beyond Immunotherapy
The microbiome’s role in cancer treatment doesn’t stop at immunotherapy. Early research is testing FMT alongside chemotherapy in pancreatic cancer, and other tools are on the horizon: postbiotics (metabolites without live microbes), targeted probiotics, dietary prebiotics, and even engineered microbial blends. Microbiome interventions are moving from “gut health” into mainstream oncology—and for those of us who have long emphasized the body as an interconnected system, it’s gratifying to see what was once dismissed as “poop talk” becoming serious oncology science.
FMT in Practice
Here’s where things stand today:
Managing side effects – At MD Anderson, FMT is already being used to treat stubborn checkpoint-related colitis, with success rates above 80%. Memorial Sloan Kettering has reported similar results. This isn’t about shrinking tumors, but it shows FMT can be delivered safely in cancer patients.
Targeting tumor response – In Montréal, Canada’s first oncology FMT trial in melanoma showed early signs of benefit. Cleveland Clinic is preparing similar studies in bladder cancer. These are still early steps, but they hint at real potential.
For now, using FMT to boost treatment response is only happening in clinical trials—but the direction is clear.
Thaena and the Rise of Postbiotics
Because FMT is messy—literally and logistically—companies are looking for cleaner ways to capture the benefit without the baggage. ThaenaBiotic® is one example: a postbiotic derived from human stool, stripped of live microbes but rich in microbial metabolites. The appeal is obvious: deliver the “signals” of a healthy microbiome without the infection risks of transplant.
ThaenaBiotic® is now available through some integrative clinics and even direct-to-consumer. Too good to be true? Maybe. There are still no published human cancer outcomes; reports so far are anecdotal, though the company is actively collecting data. For now, it’s a promising but experimental step between FMT and more precise microbiome therapies. The bottom line: it’s unlikely to cause harm, and they even back it up with a “Good Sh!t Guarantee”—if you try ThaenaBiotic® and don’t love it, they’ll buy it back.
Probiotics During Immunotherapy: Friend or Foe?
Probiotics are often thought of as a “gut goodie”—they can support barrier function, digestion, and immune tone. But in the context of immune checkpoint inhibitors (ICIs), the story isn’t so simple. Some studies suggest broad-spectrum probiotics may actually blunt ICI responses. The concern is that flooding the gut with just a few strains could oversimplify the microbiome and crowd out the diversity that seems critical for success. This is why I often test rather than guess—we’re in an era of precision treatment, and our microbiome strategies should match.
Spotlight on “Hero Bugs”
Not all microbes act the same. A few species keep popping up in immunotherapy research:
Akkermansia muciniphila – often depleted in patients who don’t respond to ICIs. When it’s present, outcomes look better, possibly by strengthening the gut barrier and stimulating immune crosstalk.
Clostridium butyricum – a butyrate-producing strain linked to improved ICI tolerance and enhanced anti-tumor immunity in some early studies.
Bacteroides fragilis – shown in mouse models to boost CTLA-4 blockade, partly by priming dendritic cells and T-cell activity.
These aren’t theoretical anymore—we are already using targeted strains like these in practice as part of broader microbiome-focused oncology support, while the evidence base continues to build.
What About Stool Testing?
In my practice, I do use stool testing. Panels like GI-MAP or Genova’s GI Effects measure microbes, digestive function, inflammation markers, and sometimes short-chain fatty acids. The results can provide useful context and help guide how we support gut health during cancer care. But it’s important to remember: detecting microbial DNA is not the same as finding an active infection. Results can reflect normal shedding, microbial die-off, or sometimes an absence of shedding altogether. These panels are best seen as a snapshot—not a diagnosis—and should always be interpreted within the bigger clinical picture.
Beyond FMT, Probiotics, and Postbiotics
The microbiome toolbox is bigger than it looks. Researchers are exploring:
Prebiotics and synbiotics – the “food” for your gut bugs: fibers and plant compounds that promote beneficial microbes and short-chain fatty acid production.
Paraprobiotics – heat-killed probiotics that can still modulate immunity. In preclinical studies, they’ve reduced inflammation and slowed colitis-associated colorectal cancer.
Microbial metabolites – delivering signaling molecules directly, like butyrate or punicic acid, to influence immune cells and reshape the tumor microenvironment.
Precision interventions – advanced diagnostics that may soon allow us to tailor microbiome therapies to the individual.
Want to hear more about a topic?
Where Does This Leave Us?
Right now, FMT is mainly used in oncology to manage immunotherapy side effects—not to cure cancer. Early trials suggest it may help re-sensitize tumors, but the evidence isn’t mature yet. Postbiotics like Thaena could prove safer and more scalable, but they’re still experimental.
And of course, we can’t talk about the microbiome without talking about diet. A nourishing, organic, whole-foods diet supports immunity, reduces side effects, and helps the body weather chemotherapy or radiation. Paired with movement, stress reduction, and metabolic support, your meals become more than fuel—they become part of your treatment team. The gut microbiome isn’t just about digestion; it’s an immune training ground.
Takeaways for Patients
Gut health matters in cancer outcomes.
Diet, lifestyle and prebiotics are safe, low-risk ways to support your microbiome right now.
Tools like FMT and postbiotics are promising, FMT not widely available outside of clinical trials, but postbiotics are.
Very helpful! You should be giving my GastroANP talk this PM doc! :)
Really useful article! I'm definitely curious about Thaena and if their studies actually show promising results, and how they find their unicorn poopers 😂